Form 8-K - Current report:
SEC Accession No. 0001607062-17-000033
Filing Date
2017-01-20
Accepted
2017-01-20 16:01:37
Documents
5
Period of Report
2017-01-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K gnbt01192017form8k.htm 8-K 918046
2 EXHIBIT 10.1 ex10_1.htm EX-10.1 302342
3 GRAPHIC hivww.jpg GRAPHIC 23492
4 GRAPHIC malaria1.jpg GRAPHIC 27323
5 GRAPHIC malaria2.jpg GRAPHIC 20520
  Complete submission text file 0001607062-17-000033.txt   1320522
Mailing Address 33 HARBOUR SQ STE 202 TORONTO ONTARIO CA A1 M5J 2G2
Business Address 33 HARBOUR SQ STE 202 TORONTO ONTARIO CANADA A1 M5J 2G2 4163642551
GENEREX BIOTECHNOLOGY CORP (Filer) CIK: 0001059784 (see all company filings)

EIN.: 820490211 | State of Incorp.: DE | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 000-25169 | Film No.: 17538573
SIC: 2834 Pharmaceutical Preparations